Provided is the use of a drug that inhibits complement activity, an IL-2 inhibitor and at least one other immunosuppressive drug that does not cause nephrotoxicity, in the manufacture of a medicament for prolonging survival of a kidney allograft in a mammal. The composition may include the drug LF15-0195.